Health-related quality of life in two randomized controlled trials of phentermine/topiramate for obesity: What mediates improvement?
The DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
Purpose Phentermine/topiramate combination therapy resulted in significant weight loss and improvements in cardiometabolic risk factors in patients with obesity/overweight in two published 56-week randomized, placebo-controlled trials (EQUIP and CONQUER). The purpose of the current study was to examine whether phentermine/topiramate is also associated with greater improvements in health-related quality of life (HRQOL) and whether HRQOL improvements are solely attributable to weight reduction.Methods Patients in EQUIP (n = 751) had a body mass index (BMI) ≥ 35 with no obesity-related comorbidity. Patients in CONQUER (n = 1623) had a BMI ≥ 27 and ≤ 45 and at least two obesity-related comorbid conditions. HRQOL was assessed with Impact of Weight on Quality of Life-Lite (IWQOL-Lite) and Medical Outcomes Study Short Form (SF-36) (CONQUER only).Results Significant improvements in both obesity-specific and physical HRQOL were observed at 56 weeks in both trials (p < .0001). In EQUIP, BMI reduction fully mediated improvements in IWQOL-Lite total score (p < .0001). In CONQUER, both BMI reduction (all p values < .0001) and change in depressive symptoms (all p values < .025) were significant mediators of improved IWQOL-Lite total score and SF-36 Physical Component Summary score. Gender, psychiatric history, and baseline triglycerides moderated these relationships.Conclusions Both trials demonstrated that treatment with phentermine/topiramate improved HRQOL compared with placebo. Although reduction in BMI accounted for the majority of improvements in obesity-specific and physical HRQOL, decrease in depressive symptoms was also a significant mediator. Results highlight the predominance of weight reduction as a key factor in improving HRQOL in obesity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“RCTs [75][76][77] suggest weight-loss efficacy greater than GLP1-RAs, with mean weight loss of ≈20% (placebo-subtracted ≈18%) in adults without T2D, and 36% losing ≥25% of initial weight.”
From Approach to Obesity Treatment in Primary Care: A Review (2024) · cites this paper as [76]
Citations
The citation lists are queued
They are fetched later and appear here then.
References 42 · Cited by 24
Metadata
- Authors
- Kolotkin, R. L., Gadde, K. M., Peterson, C. A., & Crosby, R. D.
- Affiliations
- Duke University (US)
- Pennington Biomedical Research Center (US)
- Vivus (United States) (US)
- University of North Dakota (US)
- Corresponding author
- Kolotkin, Ronette L.
- Venue
- Quality of Life Research
- Published
- 2015-10-07
- Volume
- 25
- Issue
- 5
- Pages
- 1237-1244
- ISSN
- 0962-9343 (ISSN-L)
- 1573-2649
- OpenAlex
- W1826001489
- Cited by
- 24
- References
- 42
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 4 · 2022: 2 · 2021: 2 · 2020: 1 · 2019: 1 · 2018: 2 · 2017: 6 · 2016: 1
- FWCI
- 2.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Quality of Life Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Vivus (US)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- phentermine/topiramate, obesity, health-related quality of life, weight loss, mediation analysis, depressive symptoms, IWQOL-Lite, SF-36, obesity-related comorbidities, body mass index
- MeSH terms
- Topiramate, Adult, Body Weight, Depression, Female, Fructose, Health Status, Humans, Male, Middle Aged, Obesity, Phentermine, Quality of Life, Surveys and Questionnaires, Weight Loss, Body Mass Index, Randomized Controlled Trials as Topic, Outcome Assessment, Health Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Health-related quality of life in two randomized controlled trials of phentermine/topiramate for obesity: What mediates improvement? https://app.cochat.ai/papers/10.1007/s11136-015-1153-x
- The paper
- Kolotkin, R. L., Gadde, K. M., Peterson, C. A., & Crosby, R. D. (2016). Health-related quality of life in two randomized controlled trials of phentermine/topiramate for obesity: What mediates improvement? Quality of Life Research. https://doi.org/10.1007/s11136-015-1153-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.